[3/3] name: golixitinib capsules) and DZD6008 in the field of non-small cell lung cancer (NSCLC), two of which will be announced in the form of oral reports.

China NMPA Conditionally Approves Golixitinib Capsules for Market

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaPharma #OncologyInnovation #Golixitinib #PTCL #Dizal #NMPA #DengYueMedicine #PharmaceuticalExports #JAKInhibitor #ChineseInnovativeDrugs